$TVTX
Travere Therapeutics, Inc. Stock $tvtx

$tvtx Overview Financials Valuation SEC Filings Company Website

2018 Q2 Form 10-Q Financial Statement

#000143853318000016 Filed on May 01, 2018

Income Statement

Concept	2018 Q2	2018 Q1	2017 Q1
Revenue	$41.34M	$38.43M	$33.62M
YoY Change	6.54%	14.31%	15.9%
Cost Of Revenue	$1.178M	$1.613M	$709.0K
YoY Change	47.8%	127.5%	-6.34%
Gross Profit	$40.16M	$36.82M	$32.91M
YoY Change	5.67%	11.87%	16.49%
Gross Profit Margin	97.15%	95.8%	97.89%
Selling, General & Admin	$25.10M	$26.47M	$23.12M
YoY Change	-12.95%	14.51%	20.86%
% of Gross Profit	62.5%	71.89%	70.23%
Research & Development	$34.46M	$24.64M	$20.86M
YoY Change	76.88%	18.1%	42.18%
% of Gross Profit	85.81%	66.91%	63.38%
Depreciation & Amortization	$4.640M	$4.348M	$4.284M
YoY Change	4.5%	1.49%	10.1%
% of Gross Profit	11.55%	11.81%	13.02%
Operating Expenses	$62.90M	$56.34M	$48.03M
YoY Change	20.04%	17.31%	28.94%
Operating Profit	-$21.56M	-$17.91M	-$14.41M
YoY Change	58.55%	24.32%	74.83%
Interest Expense	-$1.057M	-$1.155M	-$132.0K
YoY Change	60.64%	775.0%	-19.02%
% of Operating Profit
Other Income/Expense, Net	-$602.0K	-$237.0K	$1.254M
YoY Change	-61.31%	-118.9%	-108.72%
Pretax Income	-$22.16M	-$18.15M	-$13.15M
YoY Change	46.25%	37.97%	-314.03%
Income Tax	$167.0K	$229.0K	-$2.064M
% Of Pretax Income
Net Earnings	-$22.33M	-$18.38M	-$11.09M
YoY Change	68.79%	65.72%	-198.88%
Net Earnings / Revenue	-54.02%	-47.82%	-32.99%
Basic Earnings Per Share	-$0.56	-$0.46	-$0.29
Diluted Earnings Per Share	-$0.56	-$0.46	-$0.32
COMMON SHARES
Basic Shares Outstanding	39.94M shares	39.66M shares	38.05M shares
Diluted Shares Outstanding		39.66M shares	39.16M shares

Balance Sheet

Concept	2018 Q2	2018 Q1	2017 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$255.7M	$264.0M	$248.2M
YoY Change	-13.61%	6.39%	11.61%
Cash & Equivalents	$89.31M	$61.12M	$41.87M
Short-Term Investments	$166.4M	$202.9M	$206.3M
Other Short-Term Assets	$5.500M	$4.600M	$6.900M
YoY Change	-8.33%	-33.33%	-40.52%
Inventory	$5.388M	$5.142M	$4.751M
Prepaid Expenses
Receivables	$12.32M	$12.98M	$15.43M
Other Receivables	$0.00	$0.00	$47.20M
Total Short-Term Assets	$278.9M	$286.8M	$322.4M
YoY Change	-12.75%	-11.04%	8.28%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.455M	$3.042M	$2.428M
YoY Change	36.02%	25.29%	482.25%
Goodwill	$936.0K	$936.0K	$936.0K
YoY Change	0.0%	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments	$15.00M	$15.00M
YoY Change
Other Assets	$5.351M	$6.457M	$3.661M
YoY Change	47.49%	76.37%	96.93%
Total Long-Term Assets	$212.2M	$214.0M	$188.0M
YoY Change	13.2%	13.84%	-10.21%
TOTAL ASSETS
Total Short-Term Assets	$278.9M	$286.8M	$322.4M
Total Long-Term Assets	$212.2M	$214.0M	$188.0M
Total Assets	$491.1M	$500.8M	$510.4M
YoY Change	-3.15%	-1.88%	0.65%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$7.847M	$9.423M	$4.671M
YoY Change	-13.54%	101.73%	0.52%
Accrued Expenses	$35.27M	$31.64M	$30.19M
YoY Change	27.8%	4.81%	48.06%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$45.40M
YoY Change
Total Short-Term Liabilities	$103.5M	$56.53M	$76.56M
YoY Change	29.98%	-26.16%	14.92%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$45.20M	$44.60M
YoY Change	-100.0%	1.35%	1.59%
Other Long-Term Liabilities	$4.880M	$4.617M	$3.857M
YoY Change	26.72%	19.7%	33.51%
Total Long-Term Liabilities	$4.880M	$4.617M	$3.857M
YoY Change	26.72%	19.7%	33.51%
TOTAL LIABILITIES
Total Short-Term Liabilities	$103.5M	$56.53M	$76.56M
Total Long-Term Liabilities	$4.880M	$4.617M	$3.857M
Total Liabilities	$203.2M	$201.3M	$209.4M
YoY Change	-3.86%	-3.88%	11.49%
SHAREHOLDERS EQUITY
Retained Earnings	-$208.0M	-$185.7M	-$129.0M
YoY Change	46.26%	43.95%	139.19%
Common Stock	$497.2M	$486.7M	$430.4M
YoY Change	13.35%	13.09%	15.28%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$288.0M	$299.5M	$300.9M
YoY Change
Total Liabilities & Shareholders Equity	$491.1M	$500.8M	$510.4M
YoY Change	-3.15%	-1.88%	0.65%

Cashflow Statement

Concept	2018 Q2	2018 Q1	2017 Q1
OPERATING ACTIVITIES
Net Income	-$22.33M	-$18.38M	-$11.09M
YoY Change	68.79%	65.72%	-198.88%
Depreciation, Depletion And Amortization	$4.640M	$4.348M	$4.284M
YoY Change	4.5%	1.49%	10.1%
Cash From Operating Activities	-$2.760M	-$14.73M	-$3.410M
YoY Change	-150.46%	332.08%	-4.48%
INVESTING ACTIVITIES
Capital Expenditures	-$3.730M	$39.00K	$838.0K
YoY Change	23.92%	-95.35%	3391.67%
Acquisitions
YoY Change
Other Investing Activities	$31.65M	-$12.60M	$8.440M
YoY Change	-32.36%	-249.29%	-217.88%
Cash From Investing Activities	$27.91M	-$20.85M	$4.130M
YoY Change	-36.22%	-604.87%	-142.32%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	3.080M	-$2.702M	150.0K
YoY Change	-262.11%	-1901.33%	-116.13%
NET CHANGE
Cash From Operating Activities	-2.760M	-$14.73M	-3.410M
Cash From Investing Activities	27.91M	-$20.85M	4.130M
Cash From Financing Activities	3.080M	-$2.702M	150.0K
Net Change In Cash	28.23M	-$38.28M	870.0K
YoY Change	-40.35%	-4499.66%	-106.1%
FREE CASH FLOW
Cash From Operating Activities	-$2.760M	-$14.73M	-$3.410M
Capital Expenditures	-$3.730M	$39.00K	$838.0K
Free Cash Flow	$970.0K	-$14.77M	-$4.248M
YoY Change	-88.56%	247.76%	18.2%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2018Q1	dei	Amendment Flag AmendmentFlag	false
CY2018Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2018Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2018Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
CY2018Q1	dei	Document Period End Date DocumentPeriodEndDate	2018-03-31
CY2018Q1	dei	Document Type DocumentType	10-Q
CY2018Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001438533
CY2018Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	39943960	shares
CY2018Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2018Q1	dei	Entity Registrant Name EntityRegistrantName	Retrophin, Inc.
CY2018Q1	dei	Trading Symbol TradingSymbol	rtrx
CY2017Q4	rtrx	Accrued Liabilities Miscellaneous AccruedLiabilitiesMiscellaneous	1523000	USD
CY2018Q1	rtrx	Accrued Liabilities Miscellaneous AccruedLiabilitiesMiscellaneous	2056000	USD
CY2017Q4	rtrx	Accrued Liabilities Researchand Development Current AccruedLiabilitiesResearchandDevelopmentCurrent	6989000	USD
CY2018Q1	rtrx	Accrued Liabilities Researchand Development Current AccruedLiabilitiesResearchandDevelopmentCurrent	9553000	USD
CY2017Q4	rtrx	Accrued Liabilities Selling Generaland Administrative Current AccruedLiabilitiesSellingGeneralandAdministrativeCurrent	3896000	USD
CY2018Q1	rtrx	Accrued Liabilities Selling Generaland Administrative Current AccruedLiabilitiesSellingGeneralandAdministrativeCurrent	2058000	USD
CY2017Q4	rtrx	Accrued Royalties Noncurrent AccruedRoyaltiesNoncurrent	13095000	USD
CY2018Q1	rtrx	Accrued Royalties Noncurrent AccruedRoyaltiesNoncurrent	12939000	USD
CY2017Q4	rtrx	Accrued Royaltyand Contingent Consideration AccruedRoyaltyandContingentConsideration	6429000	USD
CY2018Q1	rtrx	Change In Fair Value Of Derivative Instruments ChangeInFairValueOfDerivativeInstruments	0	USD
CY2017Q1	rtrx	Change In Fair Value Of Derivative Instruments In Shares ChangeInFairValueOfDerivativeInstrumentsInShares	0	shares
CY2018Q1	rtrx	Change In Fair Value Of Derivative Instruments In Shares ChangeInFairValueOfDerivativeInstrumentsInShares	0	shares
CY2018Q1	rtrx	Accrued Royaltyand Contingent Consideration AccruedRoyaltyandContingentConsideration	5870000	USD
CY2017Q4	rtrx	Acquisition Related Contingent Consideration AcquisitionRelatedContingentConsideration	9100000	USD
CY2018Q1	rtrx	Acquisition Related Contingent Consideration AcquisitionRelatedContingentConsideration	9500000	USD
CY2017Q4	rtrx	Acquisition Related Contingent Consideration Noncurrent AcquisitionRelatedContingentConsiderationNoncurrent	80900000	USD
CY2018Q1	rtrx	Acquisition Related Contingent Consideration Noncurrent AcquisitionRelatedContingentConsiderationNoncurrent	82000000	USD
CY2018Q1	rtrx	Business Combination Option Agreement Contingent Consideration BusinessCombinationOptionAgreementContingentConsideration	25000000	USD
CY2018Q1	rtrx	Business Combination Option Agreement Percent Of Consideration Paid In Cash If Share Price Falls Below Share Price Threshold BusinessCombinationOptionAgreementPercentOfConsiderationPaidInCashIfSharePriceFallsBelowSharePriceThreshold	1
CY2018Q1	rtrx	Business Combination Option Agreement Purchase Price BusinessCombinationOptionAgreementPurchasePrice	65000000	USD
CY2018Q1	rtrx	Business Combination Option Agreement Purchase Price Percent Transfered By Issuance Of Equity BusinessCombinationOptionAgreementPurchasePricePercentTransferedByIssuanceOfEquity	0.8
CY2018Q1	rtrx	Business Combination Option Agreement Purchase Price Percent Transfered In Cash BusinessCombinationOptionAgreementPurchasePricePercentTransferedInCash	0.2
CY2018Q1	rtrx	Business Combination Option Agreement Share Price BusinessCombinationOptionAgreementSharePrice	21.40
CY2018Q1	rtrx	Business Combination Option Agreement Weighted Average Ten Day Share Price Which Requires All Cash Payment BusinessCombinationOptionAgreementWeightedAverageTenDaySharePriceWhichRequiresAllCashPayment	19.26
CY2017Q1	rtrx	Change In Fair Value Of Derivative Instruments ChangeInFairValueOfDerivativeInstruments	-1260000	USD
CY2017Q1	rtrx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	3344000	USD
CY2018Q1	rtrx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	3627000	USD
CY2018Q1	rtrx	Days Payable After Development Milestone Achievement DaysPayableAfterDevelopmentMilestoneAchievement	P45D
CY2017Q4	rtrx	Government Rebates Payable GovernmentRebatesPayable	5883000	USD
CY2018Q1	rtrx	Government Rebates Payable GovernmentRebatesPayable	6372000	USD
CY2017Q1	rtrx	Interest Receivablefrom Notes Receivable InterestReceivablefromNotesReceivable	325000	USD
CY2018Q1	rtrx	Interest Receivablefrom Notes Receivable InterestReceivablefromNotesReceivable	0	USD
CY2016Q4	rtrx	Legal Fee Judgment LegalFeeJudgment	2025000	USD
CY2017Q1	rtrx	Noncash Interest Expense NoncashInterestExpense	376000	USD
CY2018Q1	rtrx	Noncash Interest Expense NoncashInterestExpense	413000	USD
CY2018Q1	rtrx	Number Of Products Sold NumberOfProductsSold	3	product
CY2017Q1	rtrx	Payment Of Guaranteed Minimum Royalty PaymentOfGuaranteedMinimumRoyalty	500000	USD
CY2018Q1	rtrx	Payment Of Guaranteed Minimum Royalty PaymentOfGuaranteedMinimumRoyalty	500000	USD
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	18938000	USD
CY2018Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	9423000	USD
CY2017Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	13872000	USD
CY2018Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	12981000	USD
CY2017Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-287000	USD
CY2018Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-356000	USD
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	36018000	USD
CY2018Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	31644000	USD
CY2017Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	2000000	USD
CY2018Q1	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	2000000	USD
CY2017Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	7749000	USD
CY2018Q1	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	5693000	USD
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1015000	USD
CY2018Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1529000	USD
CY2017Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	471800000	USD
CY2018Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	486717000	USD
CY2018Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4609000	USD
CY2017Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	4171000	USD
CY2018Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	4199000	USD
CY2017Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9379000	shares
CY2017Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7093000	USD
CY2018Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10439000	shares
CY2018Q1	us-gaap	Available For Sale Securities AvailableForSaleSecurities	202939000	USD
CY2017Q4	us-gaap	Assets Assets	520346000	USD
CY2018Q1	us-gaap	Assets Assets	500794000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	325807000	USD
CY2018Q1	us-gaap	Assets Current AssetsCurrent	286803000	USD
CY2017Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	201236000	USD
CY2017Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	726000	USD
CY2018Q1	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1265000	USD
CY2017Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	201962000	USD
CY2018Q1	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	204204000	USD
CY2017Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	201236000	USD
CY2018Q1	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	202939000	USD
CY2017Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-914000	USD
CY2018Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-4245000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	41002000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	41870000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	99394000	USD
CY2018Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	61117000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	868000	USD
CY2018Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-38277000	USD
CY2018Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	168612	shares
CY2017Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	1159424	shares
CY2018Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	990810	shares
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2018Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2018Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	39373745	shares
CY2018Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	39873285	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	39373745	shares
CY2018Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	39873285	shares
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	4000	USD
CY2018Q1	us-gaap	Common Stock Value CommonStockValue	4000	USD
CY2017Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-11020000	USD
CY2018Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-18892000	USD
CY2017Q4	us-gaap	Convertible Debt ConvertibleDebt	45077000	USD
CY2018Q1	us-gaap	Convertible Debt ConvertibleDebt	45238000	USD
CY2018Q1	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	63400000	USD
CY2017Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	709000	USD
CY2018Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	1613000	USD
CY2017Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-2064000	USD
CY2018Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2017Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4284000	USD
CY2018Q1	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	0	USD
CY2018Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4348000	USD
CY2017Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	15710000	USD
CY2017Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.29
CY2018Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.46
CY2017Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.32
CY2018Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.46
CY2017Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	4000	USD
CY2018Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	10000	USD
CY2017Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.157
CY2018Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.013
CY2017Q4	us-gaap	Equity Method Investments EquityMethodInvestments	0	USD
CY2018Q1	us-gaap	Equity Method Investments EquityMethodInvestments	15000000	USD
CY2018Q1	us-gaap	Equity Method Investments EquityMethodInvestments	15000000	USD
CY2017Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1300000	USD
CY2017Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1260000	USD
CY2018Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	51046000	USD
CY2018Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	55309000	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	235863000	USD
CY2018Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	243865000	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	184817000	USD
CY2018Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	188556000	USD
CY2017Q1	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-76000	USD
CY2018Q1	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	22000	USD
CY2017Q4	us-gaap	Goodwill Goodwill	936000	USD
CY2018Q1	us-gaap	Goodwill Goodwill	936000	USD
CY2017Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-13154000	USD
CY2018Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-18149000	USD
CY2017Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2100000	USD
CY2017Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2064000	USD
CY2018Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	200000	USD
CY2018Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	229000	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-4626000	USD
CY2018Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-9330000	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-3076000	USD
CY2018Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-886000	USD
CY2017Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	574000	USD
CY2018Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	593000	USD
CY2017Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	946000	USD
CY2018Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-421000	USD
CY2017Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-146000	USD
CY2018Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	2211000	USD
CY2017Q1	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	1113605	shares
CY2018Q1	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
CY2017Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-132000	USD
CY2018Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-358000	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	-11090000	USD
CY2018Q1	us-gaap	Marketable Securities MarketableSecurities	202939000	USD
CY2017Q4	us-gaap	Liabilities Liabilities	227212000	USD
CY2017Q4	us-gaap	Marketable Securities MarketableSecurities	201236000	USD
CY2017Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1916000	USD
CY2018Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1399000	USD
CY2017Q1	us-gaap	Inventory Lifo Reserve Period Charge InventoryLIFOReservePeriodCharge	25000	USD
CY2018Q1	us-gaap	Inventory Lifo Reserve Period Charge InventoryLIFOReservePeriodCharge	816000	USD
CY2017Q4	us-gaap	Inventory Net InventoryNet	5351000	USD
CY2018Q1	us-gaap	Inventory Net InventoryNet	5142000	USD
CY2017Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	3435000	USD
CY2018Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	3743000	USD
CY2017Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	700000	USD
CY2018Q1	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	1300000	USD
CY2018Q1	us-gaap	Liabilities Liabilities	201319000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	520346000	USD
CY2018Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	500794000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	85668000	USD
CY2018Q1	us-gaap	Liabilities Current LiabilitiesCurrent	56525000	USD
CY2018Q1	us-gaap	Marketable Securities MarketableSecurities	202900000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	146000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-2702000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	4125000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-20851000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-3407000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-14734000	USD
CY2017Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-53000	USD
CY2018Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-75000	USD
CY2017Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	126000	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-18378000	USD
CY2017Q1	us-gaap	Net Income Loss Attributable To Parent Diluted NetIncomeLossAttributableToParentDiluted	-12350000	USD
CY2018Q1	us-gaap	Net Income Loss Attributable To Parent Diluted NetIncomeLossAttributableToParentDiluted	-18378000	USD
CY2017Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1254000	USD
CY2018Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-237000	USD
CY2017Q1	us-gaap	Operating Expenses OperatingExpenses	48028000	USD
CY2018Q1	us-gaap	Operating Expenses OperatingExpenses	56344000	USD
CY2017Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-14408000	USD
CY2018Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-17912000	USD
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	5556000	USD
CY2018Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6457000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	146000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-536000	USD
CY2017Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3902000	USD
CY2018Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3958000	USD
CY2017Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2472000	USD
CY2018Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	4617000	USD
CY2018Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	121000	USD
CY2017Q1	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	1068000	USD
CY2018Q1	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	7066000	USD
CY2017Q1	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	0	USD
CY2018Q1	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	29519000	USD
CY2018Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	29700000	USD
CY2017Q1	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	0	USD
CY2018Q1	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	10000000	USD
CY2017Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	3477000	USD
CY2018Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	8217000	USD
CY2017Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	838000	USD
CY2018Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	39000	USD
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2018Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2018Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2018Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3112000	USD
CY2018Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2011000	USD
CY2017Q4	us-gaap	Prepaid Taxes PrepaidTaxes	2842000	USD
CY2018Q1	us-gaap	Prepaid Taxes PrepaidTaxes	2613000	USD
CY2017Q1	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	0	USD
CY2018Q1	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	608000	USD
CY2017Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	8440000	USD
CY2018Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	26924000	USD
CY2017Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1964000	USD
CY2018Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	4256000	USD
CY2018Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	600000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3230000	USD
CY2018Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3042000	USD
CY2017Q1	us-gaap	Repayments Of Other Debt RepaymentsOfOtherDebt	250000	USD
CY2018Q1	us-gaap	Repayments Of Other Debt RepaymentsOfOtherDebt	0	USD
CY2017Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	20860000	USD
CY2018Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	24636000	USD
CY2017Q4	us-gaap	Restructuring Reserve RestructuringReserve	3549000	USD
CY2018Q1	us-gaap	Restructuring Reserve RestructuringReserve	42000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-177655000	USD
CY2018Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-185717000	USD
CY2017Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	33620000	USD
CY2018Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	38432000	USD
CY2017Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	33620000	USD
CY2018Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	38432000	USD
CY2017Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	23115000	USD
CY2018Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	26468000	USD
CY2017Q1	us-gaap	Share Based Compensation ShareBasedCompensation	7093000	USD
CY2018Q1	us-gaap	Share Based Compensation ShareBasedCompensation	4659000	USD
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	4500000	shares
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	16.16
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	293134000	USD
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	299475000	USD
CY2017Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	293134000	USD
CY2018Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	283765000	USD
CY2018Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest Adjusted Balance1 StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1	299475000	USD
CY2018Q1	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2018Q1	us-gaap	Unrecognized Tax Benefits Income Tax Penalties Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense	0	USD
CY2017Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	39158922	shares
CY2018Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	39657418	shares
CY2017Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	38045317	shares
CY2018Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	39657418	shares
CY2018Q1	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;padding-top:12px;font-size:13pt;"><font style="font-family:Arial;font-size:13pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">DESCRIPTION OF BUSINESS</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:16px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;color:#1131c1;font-style:normal;font-weight:bold;text-decoration:none;">Organization and Description of Business</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Retrophin, Inc. (“we”, “our”, “us”, “Retrophin” and the “Company”) refers to Retrophin, Inc., a Delaware corporation, as well as our direct and indirect subsidiaries. Retrophin is a fully integrated biopharmaceutical company headquartered in San Diego, California focused on the development, acquisition and commercialization of therapies for the treatment of rare diseases. We regularly evaluate and, where appropriate, act on opportunities to expand our product pipeline through licenses and acquisitions of products in areas that will serve patients with rare diseases and that we believe offer attractive growth characteristics.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;color:#424242;font-style:italic;font-weight:bold;text-decoration:none;">The Company is developing the following pipeline products:</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The Company is developing fosmetpantotenate (RE-024), a novel small molecule, as a potential treatment for </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">pantothenate kinase-associated neurodegeneration (“PKAN”). PKAN is a genetic neurodegenerative disorder that is typically diagnosed in the first decade of life. Consequences of PKAN include dystonia, dysarthria, rigidity, retinal degeneration, and severe digestive problems. There are currently no viable treatment options for patients with PKAN. Fosmetpantotenate is a phosphopantothenate replacement therapy that aims to restore levels of this key substrate in PKAN patients.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Sparsentan (RE-021) is an investigational product candidate which acts as both a potent </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">angiotensin receptor blocker (“ARB”), as well as a selective endothelin receptor antagonist (“ERA”), with in vitro selectivity toward endothelin receptor type A. The Company secured a license to sparsentan from Ligand Pharmaceuticals, Inc. and Bristol-Myers Squibb Company (who referred to it as DARA). The Company is developing sparsentan as a treatment for:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#2c2c2c;font-weight:bold;">▪</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#2c2c2c;font-weight:normal;">Focal segmental glomerulosclerosis ("FSGS")</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, which is a leading cause of end-stage renal disease and nephrotic syndrome (“NS”). There are no U.S. Food and Drug Administration ("FDA") approved pharmacologic treatments for FSGS and off-label resources are limited to ACE/ARBs, steroids, and immunosuppressant agents, which are effective in only a subset of patients.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#2c2c2c;font-weight:bold;">▪</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#2c2c2c;font-weight:normal;">Immunoglobulin A nephropathy ("IgAN</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#2c2c2c;font-weight:bold;">")</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, which is characterized by hematuria, proteinuria, and variable rates of progressive renal failure. There is no FDA approved treatment for IgAN.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The Company is a party to a joint development agreement with Censa Pharmaceuticals Inc. ("Censa"), a privately held biotechnology company focused on developing therapies for orphan metabolic diseases, to evaluate sepiapterin ("CNSA-001") for the treatment of phenylketonuria ("PKU"). CNSA-001 is an orally bioavailable form of a natural precursor of tetrahydrobiopterin ("BH4") with the potential to provide improved phenylalanine ("Phe") reduction in patients with PKU when compared to BH4.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">PKU is a rare, genetic metabolic condition in which the body cannot breakdown Phe due to a missing or defective phenylalanine hydroxylase ("PAH") enzyme. High Phe levels can lead to developmental and physical growth delay, executive function impairment, seizures, and microcephaly caused by toxic Phe accumulation in the brain.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The Company is party to a three-way Cooperative Research and Development Agreement ("CRADA") with the National Institutes of Health’s National Center for Advancing Translational Sciences and patient advocacy foundation NGLY1.org to collaborate on research efforts aimed at the identification of potential small molecule therapeutics for N-glycanase deficiency ("NGLY1").</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">NGLY1 is an extremely rare genetic disorder believed to be caused by a deficiency in an enzyme called N-glycanase-1, which is encoded by the gene NGLY1. The condition has been characterized by symptoms such as developmental delays, seizures, complex hyperkinetic movement disorders, diminished reflexes and an inability to produce tears. There are no approved therapeutic options for NGLY1 deficiency, and current therapeutic strategies are limited to symptom management.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Liquid ursodeoxycholic acid ("L-UDCA") is a liquid formulation of ursodeoxycholic acid being developed for the treatment of a rare liver disease called primary biliary cholangitis ("PBC"). The Company obtained the rights to L-UDCA in 2016 with the intention of making L-UDCA commercially available to the subset of PBC patients who have difficulty swallowing.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;color:#424242;font-style:italic;font-weight:bold;text-decoration:none;">The Company sells the following </font><font style="font-family:Arial;font-size:10.5pt;color:#424242;font-style:italic;font-weight:bold;text-decoration:none;">three</font><font style="font-family:Arial;font-size:10.5pt;color:#424242;font-style:italic;font-weight:bold;text-decoration:none;"> products:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Chenodal® (chenodiol tablets) is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age. Chenodal has also been the standard of care for cerebrotendinous xanthomatosis ("CTX") patients for more than three decades and the Company is currently pursuing adding this indication to the label.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Cholbam® (cholic acid capsules) is approved in the United States (approved and marketed in Europe for select indications as Kolbam) for the treatment of bile acid synthesis disorders due to single enzyme defects and is further indicated for adjunctive treatment of patients with peroxisomal disorders.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Thiola® (tiopronin tablets) is approved in the United States for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria.</font></div></td></tr></table></div>

Files In Submission

Name	View Source	Status
0001438533-18-000016-index-headers.html	Edgar Link	pending
0001438533-18-000016-index.html	Edgar Link	pending
0001438533-18-000016.txt	Edgar Link	pending
0001438533-18-000016-xbrl.zip	Edgar Link	pending
ex03312018101.htm	Edgar Link	pending
ex03312018102.htm	Edgar Link	pending
ex03312018103.htm	Edgar Link	pending
ex03312018104.htm	Edgar Link	pending
ex03312018311.htm	Edgar Link	pending
ex03312018312.htm	Edgar Link	pending
ex03312018321.htm	Edgar Link	pending
ex03312018322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
pipelinechartq12018.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rtrx-20180331.xml	Edgar Link	completed
rtrx-20180331.xsd	Edgar Link	pending
rtrx-20180331x10q.htm	Edgar Link	pending
rtrx-20180331_cal.xml	Edgar Link	unprocessable
rtrx-20180331_def.xml	Edgar Link	unprocessable
rtrx-20180331_lab.xml	Edgar Link	unprocessable
rtrx-20180331_pre.xml	Edgar Link	unprocessable
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TVTX
Travere Therapeutics, Inc. Stock $tvtx

2018 Q2 Form 10-Q Financial Statement

#000143853318000016 Filed on May 01, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TVTX Travere Therapeutics, Inc. Stock $tvtx

2018 Q2 Form 10-Q Financial Statement

#000143853318000016 Filed on May 01, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TVTX
Travere Therapeutics, Inc. Stock $tvtx